Condition: Metastatic Breast Cancer · Sponsor: AstraZeneca
Minimally interventional study on prevalence of emerging ESR1 mutations in liquid biopsy in three cohorts of patients with breast cancer (with and without prior therapies in metastatic setting, and during first-line aromatase inhibitor plus CDK4/6 inhibitor therapy) in comparison with patient's baseline ESR1 mutation status as defined by tissue profiling.
This description comes directly from the study's public registry record.
AstraZeneca Clinical Study Information Center · 1-877-240-9479 · information.center@astrazeneca.com
Always discuss trial participation with your own doctor first.
| Ensino E Terapia de Inovação Clínica Amo - Ética | Salvador, Estado de Bahia, Brazil | Not Yet Recruiting |
| Irmandade Da Santa Casa de Misericórdia de Porto Alegre | Porto Alegre, Rio Grande do Sul, Brazil | Not Yet Recruiting |
| Fundação Antonio Prudente - A.C. Camargo Cancer Center | São Paulo, Brazil | Not Yet Recruiting |
| Instituto D'Or de Pesquisa E Ensino - São Paulo | São Paulo, Brazil | Not Yet Recruiting |
| Research Site | São Paulo, Brazil | Recruiting |
| Sociedade Beneficente Israelita Brasileira Hospital Albert Eisntein | São Paulo, Brazil | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06417801